Literature DB >> 3925875

Comparative in vitro activities of cefpiramide and apalcillin individually and in combination.

J D Allan, G M Eliopoulos, M J Ferraro, R C Moellering.   

Abstract

The in vitro activities of cefpiramide and apalcillin were compared with those of other third-generation cephalosporins and extended-spectrum penicillins against over 1,000 clinical bacterial isolates. The activity of cefpiramide against Pseudomonas aeruginosa was comparable to those of piperacillin and cefoperazone, inhibiting 90% of strains at concentrations less than or equal to 16.0 micrograms/ml. This drug was also active against a broad range of gram-negative organisms but was generally less active than many of the other cephalosporins tested against members of the family Enterobacteriaceae. The activity of cefpiramide against gram-positive organisms was comparable to that of cefoperazone. Apalcillin, along with ceftazidime, was the most active agent tested against P. aeruginosa and Acinetobacter calcoaceticus subsp. anitratus, inhibiting 90% of these strains at concentrations less than or equal to 8 micrograms/ml. Against other gram-negative and gram-positive organisms, its activity was similar to that of piperacillin. The activities of both cefpiramide and apalcillin were significantly reduced by the presence of several plasmid-mediated beta-lactamases in a series of otherwise isogenic strains of P. aeruginosa in comparison with their activities against a parent strain which lacks these enzymes. Many strains of Enterobacter cloacae were synergistically inhibited by the combination of gentamicin with either cefpiramide (5 of 10 strains) or apalcillin (6 of 10 strains). Most strains of P. aeruginosa were synergistically inhibited by the combination of gentamicin with either cefpiramide (8 of 10 strains) or apalcillin (10 of 10 strains). However, cefoxitin antagonized the activity of both cefpiramide and apalcillin against most of these same strains.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3925875      PMCID: PMC180152          DOI: 10.1128/AAC.27.5.782

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Comparative pharmacokinetics of apalcillin and piperacillin.

Authors:  H Lode; A Elvers; P Koeppe; K Borner
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

Review 2.  Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future.

Authors:  C C Sanders; W E Sanders
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

3.  In vitro antibacterial activity of SM-1652, a new broad-spectrum cephalosporin with antipseudomonal activity.

Authors:  M Fukasawa; H Noguchi; T Okuda; T Komatsu; K Yano
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

4.  Resistance to cefamandole: derepression of beta-lactamases by cefoxitin and mutation in Enterobacter cloacae.

Authors:  T D Gootz; C C Sanders; R V Goering
Journal:  J Infect Dis       Date:  1982-07       Impact factor: 5.226

5.  In-vitro activity of Sch 29482 in comparison with other oral antibiotics.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  J Antimicrob Chemother       Date:  1982-02       Impact factor: 5.790

6.  Pharmacokinetics of cefpiramide (SM-1652) in humans.

Authors:  K Nakagawa; M Koyama; H Matsui; C Ikeda; K Yano; N Nakatsuru; K Yoshinaga; T Noguchi
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

7.  Antibacterial activities of SM-1652 compared with those of other broad-spectrum cephalosporins.

Authors:  M Kato; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

8.  In vitro activity of apalcillin compared with that of other new penicillins and anti-Pseudomonas cephalosporins.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

9.  Multiply resistant viridans streptococci: susceptibility to beta-lactam antibiotics and comparison of penicillin-binding protein patterns.

Authors:  B F Farber; G M Eliopoulos; J I Ward; K L Ruoff; V Syriopoulou; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

10.  PC-904, a novel broad-spectrum semisynthetic penicillin with marked antipseudomonal activity: microbiological evaluation.

Authors:  H Noguchi; Y Eda; H Tobiki; T Nakagome; T Komatsu
Journal:  Antimicrob Agents Chemother       Date:  1976-02       Impact factor: 5.191

View more
  5 in total

Review 1.  In vitro antibacterial effects of cephalosporins.

Authors:  J D Williams; F Moosdeen
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  High hepatic excretion in humans of cefpiramide, a new cephalosporin.

Authors:  J M Brogard; F Jehl; M Adloff; J F Blickle; H Monteil
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

3.  In vitro activities of ICI 194008 and ICI 193428, two new cephem antimicrobial agents.

Authors:  J D Allan; G M Eliopoulos; E Reiszner; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

Review 4.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

5.  Comparative in vitro activity of cefpiramide, a new parenteral cephalosporin.

Authors:  C Quentin; P Noury; M Titonel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.